Price movement over the last 24 hours
Amgen, Inc. vs Tractor Supply Co — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Tractor Supply Co trades at $30.5 (market cap $15.96B). The key difference: Amgen, Inc. is far larger — about 12.3× Tractor Supply Co's market cap, and Tractor Supply Co pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| AMGN | TSCO | |
|---|---|---|
Market Cap | $196.12B | $15.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $62.65 |
52-Week Low | $271.18 | $29.14 |
Enterprise Value | $241.41B | $22.14B |
Dividend Yield | 2.77% | 3.15% |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Tractor Supply (TSCO) trades at $30.43, up 1.0% on the day, with a bearish technical signal despite neutral oscillators. The company maintains stable revenue growth to $15.52B in 2025 with consistent $1.1B net income, though profit margins show slight compression. Recent earnings show mixed results with Q2 2026 expectations at $0.85 EPS. Analyst consensus is divided with 48% buy ratings and a $42.15 price target, representing 38% upside potential from current levels.
TSCO presents a compelling valuation case with P/E of 14.99 below industry averages, supported by strong ROE of 45.5% and dividend payments. Key risks include recent earnings misses, competitive retail pressures, and consumer spending sensitivity. The stock's current technical weakness near support at $29 creates potential entry opportunity for value-oriented investors seeking rural retail exposure.
Trailing returns across standard periods
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →